Abstract
Endometrial cancer is the most common gynecologic malignancy and the fourth most common malignancy overall in the United States, with approximately 43,000 new cases diagnosed annually [1]. An estimated 287,000 new cases were diagnosed worldwide in 2008 [2]. Approximately 8000 women will die from uterine cancer in the United States annually [1]. The management of endometrial carcinoma is one of the most controversial in gynecologic oncology. There have been key advancements in recent years regarding staging, surgical approaches, role of lymphadenectomy, and role of adjuvant therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
